Back

Organon & Co

Ticker: OGN ISIN: US68622V1061
Add to portfolio Portfolio analysis in 2min
Stock Mid-cap Dividend payer
Market cap
$3.84B
P/E
2.95
Forward P/E
5.03
Profit margin
20.30%
Revenue growth QoQ
4.10%
Div. yield
7.51%
Beta
0.80
$13.75 0.00%
Price as of 2026-08-25 · NYSE

Performance by timeframe

Rolling returns
1 Month +1.70%
6 Months +83.63%
1 Year +52.83%
5 Years -13.33% p.a.-51.07%
Since inception -12.03% p.a.-49.18%
Calendar year returns
YTD +92.81%
2025 -50.71%
2024 +9.92%
2023 -45.12%
2022 -4.86%

Key stats

Market cap
3.84B
P/E
2.95
Dividend yield
7.51%
Beta
0.80
52-week range
12.85 - 22.70
50-day MA
15.84
200-day MA
18.94
Section 1

Business overview

Company profile data from fundamentals.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 0.00%
ROA 7.91%
Profit margin 20.30%
Operating margin 24.65%
Revenue/share TTM 24.98
Revenue TTM 6.41B
EBITDA 1.76B
Gross profit TTM 3.89B
Beta 0.80

Valuation

Trailing P/E 2.95
Forward P/E 5.03
P/B 7.79
P/S 0.60
EV/EBITDA 7.59
EV/Revenue 1.85
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 4.14
Quarterly earnings growth 5.08%
Revenue TTM 6.41B
Reported quarters 18
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 7.51%
Forward annual div. yield 7.51%
Dividend per share 1.1200
Payout ratio 27.38%
Ex-dividend date 2024-11-12
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $29.29
Analyst rating 3.3333

Ownership & short interest

Shares outstanding 257.54M
Shares float 256.70M
Institutional ownership 81.64%
Insider ownership 17.70%
Short ratio 5.42
Short % of float 7.91%

Details

Instrument metadata and source update timestamps.

Symbol OGN
Name Organon & Co
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US68622V1061
Country USA
Code + exchange OGN.NYSE
Last price date 2024-12-31
Fundamentals updated 2025-01-01

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.